These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 25142189)
1. A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia. Bradstock KF; Link E; Collins M; Di Iulio J; Lewis ID; Schwarer A; Enno A; Marlton P; Hahn U; Szer J; Cull G; Seymour JF; Br J Haematol; 2014 Dec; 167(5):618-25. PubMed ID: 25142189 [TBL] [Abstract][Full Text] [Related]
2. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Vadhan-Raj S; Trent J; Patel S; Zhou X; Johnson MM; Araujo D; Ludwig JA; O'Roark S; Gillenwater AM; Bueso-Ramos C; El-Naggar AK; Benjamin RS Ann Intern Med; 2010 Sep; 153(6):358-67. PubMed ID: 20855800 [TBL] [Abstract][Full Text] [Related]
3. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980 [TBL] [Abstract][Full Text] [Related]
8. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia]. Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381 [TBL] [Abstract][Full Text] [Related]
9. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446 [TBL] [Abstract][Full Text] [Related]
10. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial). Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421 [TBL] [Abstract][Full Text] [Related]
11. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Schmidt E; Thoennissen NH; Rudat A; Bieker R; Schliemann C; Mesters RM; Zühlsdorf M; Müller-Tidow C; Berdel WE Ann Oncol; 2008 Sep; 19(9):1644-9. PubMed ID: 18453519 [TBL] [Abstract][Full Text] [Related]
12. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. Henke M; Alfonsi M; Foa P; Giralt J; Bardet E; Cerezo L; Salzwimmer M; Lizambri R; Emmerson L; Chen MG; Berger D J Clin Oncol; 2011 Jul; 29(20):2815-20. PubMed ID: 21670447 [TBL] [Abstract][Full Text] [Related]
14. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. Blijlevens N; de Château M; Krivan G; Rabitsch W; Szomor A; Pytlik R; Lissmats A; Johnsen HE; de Witte T; Einsele H; Ruutu T; Niederwieser D; Bone Marrow Transplant; 2013 Jul; 48(7):966-71. PubMed ID: 23241739 [TBL] [Abstract][Full Text] [Related]
15. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. Le QT; Kim HE; Schneider CJ; Muraközy G; Skladowski K; Reinisch S; Chen Y; Hickey M; Mo M; Chen MG; Berger D; Lizambri R; Henke M J Clin Oncol; 2011 Jul; 29(20):2808-14. PubMed ID: 21670453 [TBL] [Abstract][Full Text] [Related]
16. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Damon LE; Johnston LJ; Ries CA; Rugo HS; Case D; Ault K; Linker CA Cancer Chemother Pharmacol; 2004 Jun; 53(6):468-74. PubMed ID: 15138711 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568 [TBL] [Abstract][Full Text] [Related]
18. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204 [TBL] [Abstract][Full Text] [Related]
19. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle. Ruutu T; Koivunen E; Nousiainen T; Pelliniemi TT; Almqvist A; Anttila P; Jantunen E; Koistinen P; Koponen A; Mikkola M; Oksanen K; Pulli T; Remes K; Sarkkinen R; Silvennoinen R; Timonen T; Vanhatalo S; Elonen E; Eur J Haematol; 2004 Jan; 72(1):38-44. PubMed ID: 14962261 [TBL] [Abstract][Full Text] [Related]
20. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group. Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]